Neuropore Therapies Appoints Dr. Joseph S. McCracken to Board of Directors
San Diego, CA – October 29, 2019 8:01am (EDT) – Neuropore Therapies, Inc., a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for the underlying causes of neurodegenerative disease, announced today the appointment of Joseph S. McCracken, DVM, MS to its board of directors.
“Dr. McCracken’s extensive business development, transactional and operational experience make him a valuable addition to our board” said Errol De Souza, Ph.D., President and Chief Executive Officer of Neuropore. “It is a true pleasure to welcome Joe to Board and we look forward to his advice and guidance as we transition the Company into progressing more compounds into clinical development and forming strategic collaborations.”
Joseph S. McCracken currently advises biopharmaceutical companies on the design and implementation of corporate strategy and business development initiatives and serves on the Boards of Alkahest, Inc., Modalis Therapeutics, Kindred Biosciences, Regimmune Inc., and Savara Pharmaceuticals. Dr. McCracken was previously Vice President and Global Head of Business Development & Licensing for Roche Pharma, where he was responsible for Roche Pharma’s global in-licensing and out-licensing activities. From October 2009 until July 2011, he was General Manager, Roche Pharma Japan & Asia Regional Head, and Roche Partnering. Prior to joining Roche Pharma, Dr. McCracken held the position of Vice President, Business Development at Genentech for nearly 10 years, and previously held similar positions at Aventis Pharma and Rhone-Poulenc Rorer. Dr. McCracken holds a Bachelor of Science in Microbiology, a Master of Science in Pharmacology and a Doctorate in Veterinary Medicine from The Ohio State University.
“I am thrilled to join the Neuropore Board,” said Dr. McCracken. “Neuropore’s discovery platforms in neuroinflammation and autophagy are very promising for the treatment of both neurodegenerative disorders as well as peripheral autoimmune diseases. I look forward to providing guidance on multiple fronts including business strategy and collaborations as Neuropore transitions to the next phase of its evolution as an emerging clinical development organization.”
For further information
Media Contact Neuropore:
Errol De Souza, Ph.D.
President & Chief Executive Officer
T +1 858-273-1831
Errol.DeSouza@neuropore.com
About Neuropore Therapies, Inc.
Neuropore Therapies Inc. is a San Diego, California based biopharmaceutical company developing novel disease modifying small molecule therapeutics for the treatment of neurodegenerative disorders. Neuropore’s therapeutic candidates block the neurotoxic oligomeric aggregates of misfolded proteins which are the primary drivers of disease pathology by preventing the induction of damaging neuroinflammation mechanisms common to many neurodegenerative disorders. By targeting the underlying mechanisms by which neuroinflammation drives a vicious cycle of protein pathology and neurodegeneration, Neuropore’s therapeutic candidates may have broad applications in slowing disease progression and improving symptoms across a wide range of neuro-inflammatory / neuro-degenerative disorders.